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xtracellular matrix (ECM) fragments or cryptic sites
unmasked by proteinases have been postulated to affect
tissue remodeling and cancer progression. Therefore,
the elucidation of their identities and functions is of great
interest. Here, we show that matrix metalloproteinases
(MMPs) generate a domain (DIII) from the ECM macromole-
cule laminin-5. Binding of a recombinant DIII fragment to
epidermal growth factor receptor stimulates downstream
signaling (mitogen-activated protein kinase), MMP-2 gene
E
 
expression, and cell migration. Appearance of this cryptic
ECM ligand in remodeling mammary gland coincides with
MMP-mediated involution in wild-type mice, but not in tissue
inhibitor of metalloproteinase 3 (
 
TIMP-3
 
)–deﬁcient mice,
supporting physiological regulation of DIII liberation. These
ﬁndings indicate that ECM cues may operate via direct
stimulation of receptor tyrosine kinases in tissue remodeling,
and possibly cancer invasion.
 
Introduction
 
Disruption of ECM architecture via degradation of its
component macromolecules by proteolytic enzymes, such
as metalloproteinases, plays a crucial role in tissue remodel-
ing. Proteolysis creates migratory paths, frees signaling
molecules including growth factors latently immobilized
within the ECM, and generates biologically active neo-
epitopes and ECM fragments (Foda and Zucker, 2001;
Kleinman et al., 2001; Simian et al., 2001; Stetler-Stevenson
and Yu, 2001; Egeblad and Werb, 2002). These cues may
direct the invasion of surrounding stroma by normal epi-
thelial cells during tissue regeneration and remodeling, or
trigger mobility of cancerous epithelial cells in the initial
phases of metastasis.
Basement membranes (BMs)* are thin sheets of specialized
ECM supporting epithelial cell layers. A major component
of epithelial BM, laminin-5 (Ln-5), has been implicated in
cell migration and tumor invasion. Ln-5 has a cruciform
structure with one long and three short arms. The coiled-
coil structure of the long arm is formed by three chains (
 
 
 
3,
 
 
 
3, and 
 
 
 
2) covalently linked via interchain disulfide bonds
(Yurchenco and Cheng, 1993). The rodlike regions in the
short arms are composed of EGF-like repeats intercalated
with globular domains (Engel et al., 1994). Several laboratories
have reported enhanced expression of Ln-5, especially its 
 
 
 
2
subunit, at sites of tumor cell penetration in histological
specimens of breast, colon, gastric, and other types of cancers
(Pyke et al., 1994; Kagesato et al., 2001; Yamamoto et al.,
2001; Niki et al., 2002). Ln-5 could facilitate tumor invasion
by promoting at least two relevant cellular functions; adhesion
and migration.
Recently, we have shown that binding of the globular
LG3 domain (
 
 
 
3 chain) of Ln-5 to integrin 
 
 
 
3
 
 
 
1 mediates
cell adhesion and cell migration (Shang et al., 2001). Adhesion
may also be promoted by the Ln-5 receptor 
 
 
 
6
 
 
 
4 integrin,
which is involved in formation of hemidesmosomes (Borradori
and Sonnenberg, 1999). Robust cell migration on Ln-5 was
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shown to be triggered by cleavage of its 
 
 
 
2-chain by MMP-2
(Giannelli et al., 1997) and MT1-MMP (Koshikawa et al.,
2000; Gilles et al., 2001). The suggested cleavage sites imply
the liberation of the entire Ln-5 
 
 
 
2 short arm (domains III,
IV, and V) as well as of domains IV and V, or domain III
alone. A fragment comprising domains IV and V has re-
cently been found to mediate integration of Ln-5 into the
ECM and to promote cell adhesion (Gagnoux-Palacios et
al., 2001). Domain III is comprised of EGF-like repeats, and
for this reason seems especially interesting. Not only is its
structure reminiscent of epidermal growth factor receptor
(EGFR) ligands, but several studies with synthetic peptides
or laminin-1 (Ln-1) fragments containing EGF-like repeats
have demonstrated effects on cell migration (Salo et al.,
1999; Kleinman et al., 2001), possibly involving EGFR
(Panayotou et al., 1989). Given the multi-domain architec-
ture of Ln-5, it seems conceivable that other receptors in ad-
dition to integrins interact with one of its many potential
ligand sites to mediate its diverse cellular functions.
Here, we address the hypothesis that domain III of the
Ln-5 
 
 
 
2-chain is a cryptic migratory signal liberated by
MMP action. We have produced domain III recombinantly
(rDIII), attempted to assign the migratory activity of cleaved
Ln-5 to this specific fragment, and investigated a possible
engagement of EGFR. Also, we have studied the in vivo pro-
teolytic generation of this ECM fragment.
Figure 1. Characterization of DIII of 
Ln-5  2-chain. (A) Schematic depiction 
of DIII. rDIII encompasses the most 
COOH-terminal 3.5 EGF-like repeats 
( 2III5, 4, 3, and COOH-terminal part of 
2) of rat Ln-5  2-chain DIII. Six cysteines 
(filled circles) highlight the EGF-like 
domain signature, and the LE repeat 
signature is characterized by eight 
cysteines and an additional loop. The 
position of rDIII within the Ln-5 cruciform 
structure and the products of MMP 
cleavage are shown. (B) Characterization 
of rDIII using SDS-PAGE and WB. In 
SDS-PAGE (two left panels), rDIII 
resolved as a single band under both 
nonreducing and reducing conditions. 
Purified rDIII was judged to be better 
than 95% homogenous by Coomassie 
blue staining. In WB of reducing PAGE 
(two right panels), the rDIII band was 
recognized by both 2778 and anti-His-tag, 
as expected. A much fainter, higher mol 
wt band was also visible, which is likely 
dimerized rDIII. The apparent mol wt 
was calculated based on pre-stained mol 
wt standard SeeBlue
® (Invitrogen).T
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Results
 
Expression and characterization of recombinant 
 
 
 
2 subunit DIII
 
Previously, we showed that MMP-2 (Giannelli et al., 1997)
and MT1-MMP cleave the 
 
 
 
2 subunit of Ln-5 (Koshikawa
et al., 2000). The positions of the MT1-MMP cleavage sites
have now been identified (Fig. 1 A; unpublished data).
Because 
 
 
 
2-chain DIII is bracketed by MMP cleavage
sites and its structure is reminiscent of EGFR ligands, we
tested the hypothesis that MMP proteolytic fragments such
as DIII may have biological activity. We produced rDIII in
baculovirus, using rat Ln-5 
 
 
 
2 cDNA as a template. The
NH
 
2
 
-terminal boundary of rDIII (D
 
414
 
 E
 
415
 
 N
 
416
 
) coincides
with the MT1-MMP cleavage site (YSG
 
⇓
 
DEN), whereas
the COOH terminus is 17 residues downstream from the
MMP-2 cleavage site (AAA
 
⇓
 
LTS), which is also recognized
by MT1-MMP (Fig. 1 A). rDIII includes an NH
 
2
 
-terminal
stretch of five amino acids (ADLGS) derived from the bacu-
lovirus vector, and a COOH-terminal His
 
6
 
 tag.
Mass spectrometry (matrix-associated laser desorption
ionization) revealed a mol wt of 21,531 for purified rDIII,
in excellent agreement with its calculated mol wt of 21,525
 
.
 
However, rDIII resolved as a major 30-kD band under re-
ducing conditions and as an 
 
 
 
20-kD band under nonreduc-
ing conditions in SDS-PAGE (Fig. 1 B). This anomalous
migration agrees with previous findings for Ln-1 fragments
containing EGF-like repeats (Mayer et al., 1993). In West-
ern blots (WBs) of reducing PAGE gels, both antibodies
2778 and anti-His recognized a 30-kD band. Both antibod-
ies reacted with a minor 50-kD band, likely a dimerized
form of rDIII. To further characterize the 30-kD band, its
NH
 
2
 
-terminal sequence was determined by automated Ed-
man degradation, and its first seven amino acids perfectly
matched the expected sequence of the cloned rDIII (unpub-
lished data). Together, these results confirm the identity of
the recombinant protein rDIII.
 
Cell surface binding of rDIII
 
To determine whether rDIII binds to the cell surface,
MDA-MB-231 breast cancer cells were incubated with
rDIII, followed by excess 2778 and fluorescently labeled
anti-IgG secondary antibody. Flow cytometry showed
dose-dependent staining of rDIII-treated cells. Saturation
of rDIII–cell surface interactions occurred at 
 
 
 
4.5 
 
 
 
M
rDIII, resulting in fluorescence 
 
 
 
12-fold higher than the
control (Fig. 2 A). Detection of rDIII with anti-His anti-
body gave similar results (unpublished data). Another re-
combinant His-tagged 
 
 
 
2 fragment, encompassing DIII to
DV (rDIII-V), did not bind to MDA-MB-231 cell surfaces
(unpublished data).
 
rDIII binding to EGFR
 
To investigate whether DIII binds to a specific receptor,
rDIII was biotinylated and incubated with MDA-MB-231
cells in the presence of bis(sulfosuccinimidyl) suberate (BS
 
3
 
).
Cells were then washed, detergent solubilized, and the ly-
sates were allowed to react with streptavidin-coated beads.
Because rDIII is EGF-like, its binding to EGFR (ErbB1)
was tested. The material adsorbed to the streptavidin beads
Figure 2. Binding of rDIII to EGFR. (A) rDIII binding to cell 
surfaces detected by flow cytometry. MDA-MB-231 cells were 
incubated with 4.5 (open black histogram) or 2  M (open gray) 
rDIII or control rabbit IgG (filled), followed by 2778, and the 
appropriate Alexa
®-conjugated secondary antibody. (B) Recovery 
of biotin–rDIII–EGFR complexes with streptavidin-coated beads. 
1.5  M biotinylated rDIII or 0.75  M EGF was incubated with 
MDA-MB-231 cells, followed by cross-linking with BS
3. After 
detergent solubilization, cell lysates were precipitated with 
streptavidin-coated beads. WB of adsorbed material with EGFR 
pAb (top) detected a distinct band of 175 kD in samples containing 
rDIII (lane 3) or EGF (lane 2), but not in control samples (lane 1, 
no ligand). To control for EGFR expression and specificity of 
cross-linking to EGFR, total MDA-MB-231 cell lysates were 
loaded in lane 4 and stripped blots were treated with anti-insulin 
receptor   antibody (bottom), respectively. (C) Immunoprecipitation 
of biotin–rDIII–EGFR complexes with antibodies to EGFR. Cells 
were treated with biotinylated rDIII or EGF and BS
3, and cell 
lysates were immunoprecipitated with EGFR mAb. Samples were 
analyzed by WB using streptavidin-HRP and ECL. A distinct band 
at 175 kD was visible for samples containing EGF (lane 2, 0.75 
 M) or rDIII (lane 3, 1.0  M, and lane 4, 1.5  M; top). There is 
no corresponding band in the control lane (lane 1; no ligand). 
Note, the resolution of the gradient gels used is not sufficient to 
distinguish between EGF or rDIII bound to EGFR, where the 
former would be expected to run at  180 kD and the latter at 
 195 kD. To ensure equal loading in each lane, the filter was 
stripped and reprobed with EGFR pAb (bottom).T
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was separated by PAGE and analyzed by WB using an
EGFR-specific antibody (Fig. 2 B). A band with a mol wt
matching that of EGFR (175,000) was detected in the pres-
ence of rDIII, whereas in the absence of ligand, no band was
evident. As further controls, parallel incubations were per-
formed with biotinylated mouse EGF, resulting again in a
band of 175 kD, and blotting with an anti-insulin 
 
 
 
-recep-
tor antibody detected insulin receptor in total lysate but not
in streptavidin-precipitated material.
In complementary experiments, biotin-tagged EGF and
rDIII were cross-linked, and EGFR was immunoprecipitated
with anti-EGFR mAb. WB with HRP streptavidin (Fig. 2 C)
revealed a band at 175 kD in the ligand-containing samples,
but not in the control sample. A stronger signal from biotin-
tagged rDIII was seen when the concentration of rDIII was
increased. Stripping the blot and reprobing with anti-EGFR
antibody demonstrated the presence of EGFR in all samples.
These results indicate that rDIII binds to EGFR.
 
EGFR autophosphorylation upon treatment with rDIII
 
MDA-MB-231 cells treated with rDIII for 5 min in the
presence of BS
 
3
 
 showed distinct EGFR phosphorylation
(Fig. 3 A). BS
 
3
 
 alone did not induce EGFR phosphoryla-
tion. In control experiments without cross-linker, significant
EGFR phosphorylation was detected in samples containing
rDIII (Fig. 3 B) or EGF, whereas control samples devoid of
ligand failed to show EGFR phosphorylation. These data
show that rDIII stimulates EGFR phosphorylation.
 
Competition receptor binding between rDIII and EGF
 
To test the specificity of rDIII binding to EGFR, MDA-
MB-231 cells were incubated with rDIII in the presence of
increasing concentrations of mouse EGF, and analyzed by
flow cytometry. As shown in Fig. 4 A, EGF decreased the
fluorescence signal of bound rDIII in a dose-dependent
fashion. This competitive displacement of rDIII by EGF
strongly supports the specificity of rDIII binding to EGFR.
In a reverse experiment, MDA-MB-231 cells were incu-
bated with 
 
125
 
I-EGF and increasing concentrations of either
cold rDIII (Fig. 4 B, top), or EGF (bottom). Data were ana-
lyzed and depicted as competition curves (Fig. 4 B). In accor-
dance with our own judgement the software “Fit option”
chose the two-site competition equations as best fits for EGF
and rDIII with P-values of P 
 
 
 
 0.0001. The calculated IC
 
50
 
for the competition assays shown in Fig. 4 B were as follows:
for EGF, IC
 
50
 
_1 
 
 
 
 0.1 nM and IC
 
50
 
_2 
 
 
 
 3.7 nM; for rDIII,
IC
 
50
 
_1 
 
 
 
 0.18 nM and IC
 
50
 
_2 
 
 
 
 1185 nM. In all displace-
ment assays performed, the IC
 
50
 
_1 for rDIII was consistently
between 0.17 and 0.2 nM, and the IC
 
50
 
_2 between 349 and
1487 nM. Variability of receptor status of MDA-MB-231
cells in various assays may be responsible for the unsteady
IC
 
50
 
_2 of rDIII. In our hands, rDIII is not able to cause a
 
 
 
50% inhibition of 
 
125
 
I-EGF binding. It is possible that the
strong tendency of rDIII to dimerize at higher concentrations
and/or the recombinant nature of rDIII, with a COOH-ter-
minal His
 
6
 
 tag and an NH
 
2
 
-terminal stretch of vector-
derived amino acids, may account for reduced binding abil-
ity of rDIII. In summary, these results suggest that rDIII
competes for 
 
125
 
I-EGF binding to more than one EGFR or
EGFR/ErbB dimer, one of which has low affinity for rDIII.
Figure 3. Induction of EGFR tyrosine phosphorylation by rDIII. 
(A) Incubation of MDA-MB-231 cells with 185 nM rDIII for 5 min 
(lane 4, top) stimulated phosphorylation of EGFR. There is no EGFR 
stimulation for the 2-min rDIII sample (lane 3), or the 5-min no 
ligand control (lane 1). To exclude nonspecific effects due to cross-
linking, cells were exposed to BS
3 in the absence of ligand (lane 2). 
To ensure that equal amounts of EGFR protein were loaded, blots 
were stripped and reprobed with EGFR pAb (bottom). (B) EGFR 
phosphorylation by 185 nM rDIII (lane 1, top) and 1.7 nM EGF (lane 
2) for 5 min in the absence of BS
3. For control, ligand was omitted 
(lane 3), and the loading controls are shown in the bottom panel.
 
Induction of extracellular signal–regulated kinase 
phosphorylation by rDIII
 
MAPK activation is a well characterized downstream signal-
ing event that follows stimulation of the growth factor re-
ceptor EGFR (Chen et al., 2001). In MCF-7 breast cancer
cells (Fig. 5 A), extracellular signal–regulated kinase 1
(ERK1; p44) and ERK2 (p42) were rapidly phosphorylated
upon rDIII treatment. Phosphorylation levels peaked 5 min
after stimulation, were maintained for 10–20 min, and re-
turned to background levels after 30 min. Stimulation of
ERK1/2 by EGF demonstrated similar kinetics, with a pro-
nounced peak at 5 min after stimulation (Fig. 5 C). In con-
trast to rDIII and EGF, rDIII-V did not stimulate ERK1/2
(Fig. 5 D). In MDA-MB-231 cells (Fig. 5 B), phosphory-
lated forms of ERK1/2 were also detected on rDIII or EGF
stimulation, but with the following distinctive features:
there was a more prominent phospho-ERK2 band consis-
tent with a higher expression of total ERK2 compared withT
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ERK1. Constitutive levels of phosphorylated ERK1/2 in
nonstimulated MDA-MB-231 cells were higher than in
MCF-7 cells, as reported previously (Seddighzadeh et al.,
1999). rDIII-induced ERK1/2 phosphorylation was com-
pletely blocked by AG1478, a selective inhibitor of EGFR
tyrosine kinase, and by 528, an EGFR-blocking antibody
(Fig. 5 E). These data strongly support our hypothesis that
rDIII induces ERK1/2 activation via binding to EGFR.
 
Stimulation of EGFR, but not ERK1/2 phosphorylation, 
by intact Ln-5
 
To investigate accessibility of DIII for receptor binding
within intact Ln-5, MDA-MB-231 cells were incubated with
rat Ln-5 under conditions similar to those used for rDIII and
EGF. After 10 min, EGFR phosphorylation was stimulated
by EGF and to a lesser extent by Ln-5 (Fig. 6), whereas at 90
min after stimulation, more pronounced receptor phosphor-
ylation was observed with Ln-5 than with EGF. However,
Ln-5 did not stimulate ERK1/2 phosphorylation at any time
point investigated (5, 20, 30, and 90 min) in either MDA-
MB-231 or MCF-7 cells, and this result was independent of
whether the cells were in suspension or adherent (unpub-
lished data). Thus, Ln-5–stimulated EGFR phosphorylation
differs from that seen with rDIII in at least two respects;
slower kinetics and absence of downstream ERK1/2 activa-
tion, suggesting that MMP-liberated DIII may have signaling
properties distinct from those of intact Ln-5.
 
Induction of MMP-2 gene expression by rDIII
 
Activated ERKs phosphorylate downstream transcription
factors that regulate gene expression (Hazzalin and Mahade-
van, 2002). We investigated a possible effect of rDIII on
gene expression using cDNA microarrays, which carried
probes for members of the integrin, protein tyrosine kinase
and MMP families, MMP inhibitors, and ECM molecules
(Seftor et al., 2001). Spiking experiments with exogenous
control RNAs allowed a 2.0-fold change in signal intensity
to be considered statistically significant (Bilban et al., 2002).
In two independent experiments (two chips), we found that
MMP-2, MMP-9, and phosphoinositide 3-kinase gene ex-
pression were up-regulated on rDIII treatment, whereas
urokinase plasminogen activator expression was down-regu-
lated (Fig. 7 A, only MMP-2 data are shown). Enhanced ex-
pression of MMP-2 by rDIII treatment was confirmed by
semi-quantitative RT-PCR (Fig. 7 B). Induction of MMP-2
gene expression was also observed in cells stimulated with
EGF, but not with intact Ln-5. To investigate whether
rDIII-induced MMP-2 gene expression is EGFR dependent,
cells were incubated with AG1478 and LA1 before treat-
ment with rDIII. Blockage of EGFR function by these com-
 
Figure 4.
 
Competitive binding of rDIII and EGF.
 
 (A) Flow cytometry. 
MDA-MB-231 cells were incubated with 2.00 
 
 
 
M rDIII, in the 
presence of increasing concentrations of EGF (0.45, 0.85, 1.25, 
and 2.00 
 
 
 
M). rDIII binding to the cell surface was detected with 
anti-His tag and Alexa
 
®
 
 488 antibodies. The fluorescence signal 
for rDIII gradually decreases with increasing EGF concentrations. 
(B) Displacement of cell surface-bound I
 
125
 
-EGF by rDIII. MDA-
 
MB-231 cells were incubated with I0.5 nM 
 
125
 
-EGF and increasing 
concentrations of cold rDIII (top) or EGF (bottom). The 0.5 nM 
(
 
 
 
0.15 
 
 
 
Ci) working concentration of I
 
125
 
-EGF was determined by 
calculating the specific binding of I
 
125
 
EGF (“specific”) based on 
total and nonspecific binding of I
 
125
 
-EGF to MDA-MB-231 cells 
(inset in bottom panel). Cells were incubated with increasing 
concentrations of I
 
125
 
-EGF in the absence (total binding; “total”) 
or presence of an excess amount (330 nM) of unlabeled EGF 
(nonspecific binding; “nonspecific”).T
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pounds inhibited induction of MMP-2 gene expression by
rDIII. These results provide independent evidence that
rDIII interacts with EGFR and triggers downstream signal-
ing, resulting in altered gene expression.
 
Stimulation of cell migration by rDIII via EGFR
 
Because EGFR and ERK1/2 have motogenic properties
(Klemke et al., 1997; Xie et al., 1998), we tested rDIII for its
ability to affect cell motility. In Transwell migration assays
Figure 5. Stimulation of ERK1/2 phosphorylation by rDIII. Time course of ERK1/2 activation after exposure to rDIII. Before lysate preparation, 
MCF-7 (A) or MDA-MB-231 (B) cells were treated with rDIII for the indicated time periods at 37 C. The ratio of phosphorylated ERK1/2 bands 
(P-ERK1/2, top panels) to total ERK1/2 protein bands (ERK1/2, bottom panels) was quantified. The control signal (no ligand) was set to 1 and 
the relative ERK phosphorylation intensity calculated and depicted as bar graphs (bottom panels). (A) ERK phosphorylation was performed 
with two distinct, purified preparations of rDIII protein (Prep. A and Prep. B). (B) One representative experiment and the mean   SD (n   3) 
of relative ERK1/2 phosphorylation intensity is depicted. ERK1/2 activation induced by EGF (C) but not by control protein rDIII-V (D). MCF-7 
cells were stimulated with EGF (C) for up to 30 min or with rDIII, rDIII-V or EGF for 5 min and phosphorylated ERK1/2 were detected as 
described in the legend to A. As compared with rDIII (lane 3, D) and EGF (lane 4, D,) no phosphorylation signal above control level (lane 1, D) 
was seen with rDIII-V (lane 2, D). (E) Dependency of ERK1/2 activation on EGFR. Before stimulation for 5 min with either rDIII (lane 5) or EGF 
(lane 2), MCF-7 cells were preincubated with either AG1478 or 528. Both EGFR inhibitors diminish phosphorylation of ERK1/2 (top panel) by 
rDIII (lanes 6 and 7) or EGF (lanes 3 and 4). The top bands ( 25 kD) in lane 4 (EGF   528) and 7 (rDIII   528) originates from the IgG light 
chain of 528. The total amount of loaded ERK1/2 protein is shown in the bottom panel.T
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with MDA-MB-231 cells on Ln-5, addition of rDIII re-
sulted in a 1.5–2-fold increase in migratory activity. Though
the increase in migration was modest, it was highly repro-
ducible in multiple independent experiments. More pro-
nounced stimulation of migration on Ln-5 was observed in
rDIII-treated MCF-7 and MCF10A cells (Fig. 8 A).
To determine whether enhancement of migration by rDIII
was dependent on rDIII binding to EGFR, Transwell assays
were performed in the presence of antibody LA1 (Fig. 8 B).
LA1 did not affect constitutive MDA-MB-231 cell migration
on coated Ln-5; however, it blocked the stimulatory effect of
rDIII or EGF. These results support the conclusion that rDIII
promotes cell migration in breast cells by engaging EGFR.
Stimulation of cell migration by cleaved Ln-5 via EGFR
MMP-2–cleaved Ln-5 acts as a more potent migratory sub-
strate than intact Ln-5 (Giannelli et al., 1997). Thus, addi-
tion of rDIII to cells that are migrating on intact Ln-5 is ex-
pected to mimic the situation where MMPs generate Ln-5
cleavage products, such as DIII, which in turn may affect
cell motility. Knowing that constitutive migration on Ln-5
does not engage EGFR, whereas rDIII or EGF induced mi-
gration on Ln-5 depends on EGFR (Fig. 8 B), we investi-
gated whether migration on MMP-2–cleaved Ln-5 depends
on EGFR. To address this issue, we first demonstrated that
Figure 6. Induction of EGFR tyrosine 
phosphorylation by intact Ln-5. Treatment of 
MDA-MB-231 cells with 1.7 nM EGF for 10 min at 
37 C results in significant phosphorylation of 175 kD 
EGFR (lane 2, left panels) over control (lane 1, 
no ligand), whereas 2.5 nM purified Ln-5 causes only 
weak EGFR phosphorylation (lane 3). Stimulation 
of cells for 90 min (right panels) with Ln-5 (lane 3) 
results in an EGFR phosphorylation signal well 
above control (lane 1). In contrast, incubation of 
cells for 90 min in the presence of EGF (lane 2) 
diminished the signal toward background level 
(lane 1).
Figure 7. Effects of rDIII on gene expression. (A) Microarray 
hybridization. Amplified RNA prepared from MCF-7 cells was 
cultured in the presence (cy3) or absence (cy5) of rDIII and 
cohybridized to the microarray containing 83 human cDNAs 
related to cancer cell metastasis (filled histogram). The open histogram 
represents RNA isolates where the cy3 and cy5 labels were switched. 
Ratios below 1.0 were inverted and multiplied by  1 to aid in their 
interpretation. The MMP-2 gene expression signal exceeded a 
twofold signal intensity change threshold, independent of the dye 
label orientation. Results are expressed as the mean   SD from six 
fluorescence signals. (B) Semi-quantitative RT-PCR. Changes in 
MMP-2 expression were assessed on the influence of 185 nM rDIII, 
2.5 nM Ln-5, or 0.17 nM EGF, with or without AG1478 or LA1. 
DMSO was added to the controls. As a control for normalization, 
GAPDH was amplified similarly to MMP-2. Amplified cDNAs of 
MMP-2 (504 bp) and GAPDH (516 bp) were resolved by agarose 
gel electrophoresis and visualized by ethidium bromide staining.T
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Figure 8. Breast cell migration stimulated 
by rDIII. (A) Micrographs of the lower 
surfaces of Transwell filters after migration of 
MDA-MB-231 (a–c), MCF-7 (d–f), or 
MCF10A (g–i) cells on coated Ln-5. The 
micrographs a, d, and g show migration 
on coated Ln-5 only. rDIII was added at 
increasing concentrations to the bottom 
(MDA-MB-231, 6 nM, b and 12 nM, c) or 
top chambers (MCF-7, 70 nM, e 185 nM, f 
and MCF10A, 70 nM, h and 460 nM, i). The 
magnification used to count and photograph 
migrated cells may differ between cell lines 
and assays depending on how heavily cells 
migrated. The results are summarized in the 
corresponding bar graphs. MDA-MB-231: 
*p (b and a)   0.0044, **p (c and a)   
2.18E-08, ANOVA p   6.38E-08; MCF-7: 
*p (e and d)   2.96E-07, **p (f and d)   3.07E-11, ANOVA p   
2.36E-16; MCF10A: *p (h and g)   6.94E-07, **p (i and g)   1.41E-07, 
ANOVA p   3.43E-11. Micrographs shown are representative for 
several independent experiments. (B) Migration of MDA-MB-231 
cells on coated Ln-5 challenged with rDIII. The effect of rDIII or EGF 
on MDA-MB-231 cell migration in the absence and presence of LA1, 
as well as constitutive migration on Ln-5 (in the absence of any stimuli) 
and its dependency on EGFR is depicted. Note that if membranes 
were not coated with Ln-5, MDA-MB-231 cells did not migrate at all 
(not depicted). To normalize values, each data point (cell number 
migrated per well) was divided by the average cell number migrated 
per well that was determined for Ln-5 (relative cell migration). Average 
cell number of Ln-5 was set to 1. Values in bar graphs represent the 
mean   SD of at least three independent experiments. No change 
detected in 5 out of 5 assays with *p (b and a)   0.97 - 0.16 (null-
hypothesis confirmed). Statistically significant changes were found in 
** 7 out of 8, *** 3 out of 3, **** 3 out of 3 and ***** 3 out of 4 assays 
with **p (c and a)   1.9E-06 – 0.0147; ***p (d and c)   8.8E-07 – 
3.6E-06; ****p (e and a)   1.37E-06 – 1.6E-05; *****p (f and e)   
8.4E-06 – 2.2E-05. (C) DIII is a cleavage product of Ln-5 and is 
detectable in conditioned medium of human MCF10A cells. WB of 
MMP-2 cleaved Ln-5 and concentrated conditioned medium were 
detected with 2778 (lanes 1–6), or D4B5 (lane 7). The bottom and 
top WBs are identical, except that the bottom panels are overexposed, 
depicting DIII more clearly. Cleavage of Ln-5 with MMP-2 for 2 h 
(lane 3), 17 h (lane 4), and 24 h (lane 5) results in the appearance of 
the  80 chain, DIII-V, and DIII. In conditioned medium from 
MCF10A cells DIII is detectable using both 2778 (lane 6) and D4B5 
(lane 7). For comparison, purified, non-MMP treated Ln-5, which is 
mainly composed of the  140 and  100 chains, was loaded in lane 
2 and rDIII in lane 1. (D) Stimulated migration of MMP-2 cleaved 
Ln-5 depends on EGFR. MCF10A cells were allowed to migrate on 
Transwell membranes, which were coated with either uncleaved 
(top panels;  MMP-2) or MMP-2-cleaved Ln-5 (bottom panels; 
 MMP-2). Cells remained untreated (left panels, Ln-5), or were 
treated with LA1 for 30 min before seeding. LA1 was added where 
indicated (right panels,  LA1). The corresponding bar graph is 
shown with *p (b and a)   0.0030; **p (c and a)   7.27E-05; 
***p (d and a)   0.1333 and ***p (d and c)   1.39E-05.T
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cleavage of Ln-5 by MMP-2 indeed liberates DIII as de-
tected with antibody 2778 (Fig. 8 C). Furthermore, we de-
tected DIII with both antibodies 2778 and D4B5 in condi-
tioned medium from MCF10A cells.
Having shown that DIII is fully released on cleavage of
Ln-5 by MMP-2, MCF10A cells were allowed to migrate on
Transwell chamber membranes, where they clearly displayed
enhanced migration on cleaved Ln-5 (Giannelli et al.,
1997). The increase in motility on cleaved Ln-5 (Fig. 8 D)
was inhibited in cells pretreated with LA1. In contrast, cells
seeded on uncleaved Ln-5 showed no enhanced migration
and were not significantly affected by the presence of LA1.
These results strongly suggest that the EGFR dependency of
cells migrating on cleaved Ln-5 is due to the presence of
EGFR-engaging fragments such as DIII.
Detection of liberated DIII at physiologically 
significant stages of mammary gland development
Our in vitro data support the hypothesis that DIII is a cryp-
tic migratory ECM cue released upon MMP-2 cleavage of
Ln-5. To investigate the physiological relevance of these
data, we tested for liberated DIII in the involuting mam-
mary gland. The stages of mammary gland involution are
well characterized with respect to MMP expression (Tal-
houk et al., 1992; Lund et al., 1996). We investigated the
presence of DIII in wild-type (WT) as well as tissue inhibi-
tor of metalloproteinase 3 (TIMP-3)–null ( / ) mice be-
cause deficiency of MMP inhibitors should favor DIII liber-
ation. TIMP-3 binds tightly to the ECM (Fata et al., 2001;
Leco et al., 2001) and interferes strongly with localized pro-
teolysis of ECM molecules such as Ln-5. To detect DIII, we
used mAb D4B5, which recognizes an epitope present on
mouse DIII only when it is liberated from Ln-5 (i.e., it is not
reactive with intact mouse Ln-5  2-chain). Mammary gland
tissue lysates from mice killed on day 10 of lactation as well
as day 1, 2, 3, 4, and 7 of involution were subjected to SDS-
PAGE and WB. In WT mice, DIII is detectable in involut-
ing tissue starting at day 2 of involution, but it is not visible
at day 1 of involution or day 10 of lactation (Fig. 9). In con-
trast, in the  /  mice, the DIII fragment is clearly detect-
able at day 10 of lactation, as well as day 1 of involution. At
day 2, 3, 4, and 7 of involution, approximately equal levels
of DIII were apparent in both WT and  /  tissue.
To confirm these results, we used a pAb that detects the
intact Ln-5  2 subunit and some proteolytic fragments.
With this reagent, DIII was not readily detected. Nonethe-
less, degraded  2 was visible at day 1 of involution in TIMP-
3–deficient mice, but not in WT mice. Interestingly, at day
3 of involution,  2 fragments were more abundant in WT
than  /  tissues.T
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The fact that we were able to detect DIII in tissues under
conditions of high MMP activity indicates the physiological
relevance of this fragment. Furthermore, the patterns of ap-
pearance of DIII in mammary gland are consistent with
previous reports in which TIMP-3–deficient involuting
mammary tissue was found to show low levels of activated
MMP-2 as early as day 1 of involution, as opposed to WT
involuting tissue, where MMP activity could not be detected
before day 3 of involution (Fata et al., 2001).
Discussion
We describe a molecular mechanism responsible for stimulat-
ing cell migration on MMP-cleaved Ln-5. The involvement
of the EGF-like domain DIII of the Ln-5  2 subunit is dem-
onstrated by the following data: (1) MMP-2 and MT1-
MMP cleave Ln-5 (Giannelli et al., 1997; Koshikawa et al.,
2000; unpublished data) excising DIII; (2) rDIII binds spe-
cifically EGFR; (3) rDIII activates downstream signaling, in-
cluding EGFR and ERK1/2 phosphorylation; and (4) rDIII
stimulates cell motility and changes in gene expression.
These findings point to several novel elements. First, they
show that MMPs can initiate precise sequences of molecular
events, including ligand-receptor binding, signal transduc-
tion, and changes in cell behavior. Second, they indicate that
EGF-like ligands for receptor tyrosine kinases (RTKs) may be
solid phase, i.e., contained within the structure of the ECM
itself (Swindle et al., 2001), or may be released as small diffus-
ible factors. Third, they imply that laminins exert their diverse
functions by interaction with different receptor families
(Kleinman et al., 2001), such as RTKs, integrins (Belkin and
Stepp, 2000), and dystroglycan (Henry and Campbell, 1999).
Several independent lines of investigation demonstrated
that rDIII unequivocally binds the RTK EGFR. By flow cy-
tometry, rDIII (but not rDIII-V) bound to the cell surface in
a saturable and dose-dependent manner and its binding was
inhibited by EGF. Cross-linking of rDIII to the cell surface
resulted in formation of a complex between rDIII and EGFR.
rDIII specifically displaced cell surface bound EGF, the best
known ligand for EGFR and the prototypical member of the
EGF-like family of growth factors (Yarden, 2001). This fam-
ily (Thompson et al., 1996) also includes TGF , amphi-
regulin (AR), heparin-binding EGF-like growth factor, beta-
cellulin, and epiregulin. EGF-like ligands bind distinct
heterodimers formed by pairing of various members of the
EGFR family (i.e., ErbB-2, -3, and -4; Schlessinger, 2000).
Whether or not rDIII binds to such heterodimers is currently
under investigation. rDIII displacement data fit well to a two-
site model, and it is tempting to speculate that EGF and DIII
may bind to partially overlapping sets of ErbB receptors, dis-
tinguished by subunit composition and/or affinity. This
would also explain the fact that DIII cannot displace EGF
binding  50%. In addition, phosphorylation of EGFR and
ERK activation of rDIII binding occurs with kinetics that
parallel those triggered by EGF (Kholodenko et al., 1999).
Our IC50 measurements suggest an affinity of rDIII for
EGFR in the nanomolar range (IC50_1, 0.17–0.2 nM;
IC50_2, 349–1487 nM), which is consistent with the rDIII
concentrations used for our other studies (92.5–185 nM
MAPK, 185 nM EGFR, 185 nM MMP-2, 6–460 nM mi-
gration). Affinity values in this range are common for ECM
molecules or fragments. For instance, the Kd of Ln-5 for its
main receptor, the  3 1 integrin, is  600 nM (Eble et al.,
1998), and the affinity of a tenascin EGF-like fragment for
EGFR is in the micromolar range (1–6  M; Swindle et al.,
2001). The IC50 of the physiological EGFR ligand AR varies
depending on its COOH-terminal amino acid residue ex-
tension (rAR84, 840 nM; rAR87, 20 nM; rAR92, 43 nM;
Thompson et al., 1996). Thus, our results provide an en-
couraging platform for studying DIII–EGFR interactions in
physiological systems.
The structure of rDIII corroborates its EGFR binding
property. Both EGF and laminin-type EGF (LE) repeats are
highly conserved folds commonly found in growth factors
and ECM proteins (Engel et al., 1994). Several LE domains
have been reported to have biological activities. For instance,
Figure 9. Detection of DIII in lysates 
of mammary gland tissue. Mammary 
lysates were resolved on a 4–12% 
Bis-Tris gradient gel in MES buffer under 
reducing conditions. D4B5 detected a 
distinct band of  20 kD that very likely 
is DIII (top panel). In contrast to WT, DIII 
could be found at day 10 of lactation 
as well as at day 1 of involution in 
TIMP-3–null ( / ) tissue. After day 1 of 
involution, DIII was detectable at all 
time points of involution in both the 
involuting and lactating mice (day 2–7 
of involution). Stripping and reprobing 
the blot with 2778 revealed unscheduled 
fragmentation of Ln-5  2 chain (bottom 
panel). Fragmentation occurred in  /  
1 d earlier than in WT mammary glands 
(day 1 of involution, WT,  / ). The 
exact identity of the various fragments in 
the range of 30–100 kD is not known. 
The Ln-5  2 chain profile at day 10 of lactation as well as at day 7 of involution does not differ between WT and  /  tissue, when detected 
with 2778 (not depicted). To ensure equal loading in each lane, blots were stripped and reprobed with Actin mAb (MAB 1501, CHEMICON 
International; middle panel).T
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LE repeats of laminin  2- and  3-chains stimulate neurite
outgrowth (Koch et al., 2000). Antibodies to DIII of Ln-5
 2-chain inhibited migration of squamous cell carcinoma
cells by  50% (Salo et al., 1999). A proteolytic fragment of
Ln-1, encompassing multiple LE domains, stimulated MMP
synthesis (Turpeenniemi-Hujanen et al., 1986), cell growth
(Terranova et al., 1986), and induced EGFR phosphoryla-
tion and S6 kinase activity (Novak-Hofer and Thomas,
1984). We have extended these observations by connecting
the biological activities of rDIII to receptor binding and
downstream signaling.
The observations that rDIII-V failed to bind to cell sur-
faces and induce ERK phosphorylation and that intact Ln-5
stimulated EGFR phosphorylation with slow kinetics, but
had no effect on ERK phosphorylation, suggest that fully re-
leased DIII may be a better ligand for EGFR. This would
agree with findings on EGF and TGF , which harbor crucial
amino acids for EGFR binding in their COOH- and possibly
NH2-terminal regions (Ogiso et al., 2002) and also with the
growing list of EGF-like molecules, proteolytically liberated
out of large multi-domain proteins as small diffusible ligands
(Kennedy et al., 1994; Qi et al., 1999; Koch et al., 2000).
In experiments testing whether rDIII binding to EGFR
affects cell growth, our results were inconclusive and need
additional investigation. However, we demonstrated that
rDIII affects cell motility. In cultured cells, rDIII produced
a dose-dependent enhancement of cell migration, which
may profoundly affect direction and positioning of cells
within tissues. Its physiological relevance was suggested by
the finding that cleavage of Ln-5 by MMP-2 releases several
fragments, including DIII. Furthermore, MMP-enhanced
cell migration on Ln-5 was EGFR dependent. Interestingly,
branching morphogenesis during lung development requires
MMP-2 and MT1-MMP, key proteases downstream of
EGFR signaling, which may act via generation of bioactive
ECM fragments (Kheradmand et al., 2002).
Cell migration and enhanced invasive potential have been
reported to coincide with induction and up-regulation of
MMPs on engagement of EGFR by EGF and other EGFR
ligands (Kondapaka et al., 1997; Ellerbroek et al., 1998; Mc-
Cawley et al., 1998; Rosenthal et al., 1998). The EGFR de-
pendent up-regulation of the MMP-2 gene by rDIII is partic-
ularly interesting because it suggests a positive feedback loop
regulating tightly coordinated ECM degradation. Collagen-
induced activation of DDR2 resulted in enhanced MMP-1
expression, leading to a negative feedback loop that may con-
trol collagen degradation (Vogel et al., 1997). Similarly, deco-
rin was found to be proteolytically degraded by MMP-2, -3,
and -7 (Imai et al., 1997), to engage EGFR (Csordas et al.,
2000), and to regulate MMP-1 gene expression in cells adher-
ing to ECM vitronectin (Huttenlocher et al., 1996).
To investigate EGFR stimulation by DIII under physio-
logical conditions, we studied post-lactational involution of
the mammary gland, a tissue remodeling system whose de-
pendence on MMP action and cell migration is well under-
stood. We detected DIII in the mammary gland at stages
when MMP remodeling of the ECM is known to occur
(Talhouk et al., 1992; Lund et al., 1996; Fata et al., 2001).
The appearance of DIII paralleled both increased MMP ac-
tivity and degradation of BM during involution. DIII was
not detectable during lactation, when little remodeling or
MMP activity is expected. These findings fit well with a pre-
vious study demonstrating that  2x is absent during lacta-
tion but appears during involution (Giannelli et al., 1999).
In TIMP-3–null mice that lack a critical MMP inhibitor,
DIII was present both during lactation and at early stages of
involution. Future studies will focus on extrapolation of our
data to the murine mammary gland system to link the ap-
pearance of DIII to in vivo EGFR stimulation.
In summary, we demonstrate that a biologically active
ligand for EGFR is excisable from the ECM macromolecule
Ln-5 by MMPs. Our findings advance the understanding of
the complex molecular interactions between ECM, MMPs,
and RTKs in tissue remodeling and cancer invasion.
Materials and methods
Antibodies
Anti-His tag (anti-His) mAb was purchased from QIAGEN. Anti–rat DIII an-
tibody 2778 was generated by injecting rabbits with rDIII, and anti–human
DIII mAb D4B5 was obtained from CHEMICON International. antibodies
528 (Santa Cruz Biotechnology, Inc.) and LA-1 (Upstate Biotechnology)
block EGFR ligand binding and were used interchangeably.
Construction and expression of rDIII
DIII cDNA was amplified by PCR using a template that spans the 3  2900
bp of the rat Ln-5  2-chain gene. The forward primer (FPRIIIBHI; 5 -
CGCGGATCCGACGAGAATCCTGACATTGAG-3 ) contained the BamHI
site, and the reverse primer encoded both an EcoRI site and a COOH-ter-
minal His6 tag (RPRIIIHIS   ERI; 5 -CGGGAATTCTCAGTGATGATGAT-
GATGATGCTGGTCCATCTGAGTCTTCAC-3 ). The PCR product had the
expected size of  720 bp and was cloned into the BamHI/EcoRI sites, five
amino acids downstream of the gp67 (acidic glycoprotein gp67) secretion
signal cleavage site, provided by the baculovirus transfer vector pACGP67-B
(BD Biosciences). rDIII/pACGP67-B was sequenced and cotransfected
into Sf9 insect cells with BaculoGold
® DNA (BD Biosciences). Amplified
high titer recombinant baculovirus was used to infect High Five™ insect
cells. After 3 d, supernatants were harvested and secreted rDIII protein was
purified using Ni-NTA agarose (QIAGEN). Purity of rDIII was judged by
Coomassie blue staining.
Flow cytometry
Cells (0.5–1   10
6) were washed with HBSS, 0.1% BSA, and incubated
with 1–45  M rDIII or rDIII-V in 50  l. After 1 h on ice and washing,
bound rDIII was stained with anti-His or 2778 antibody, followed either by
fluorescently labeled anti–mouse or –rabbit antibody Alexa
® 488 (IgG
(H L) F(ab’)2, Molecular Probes, Inc.). Washed cells were resuspended in
PBS, 1% HCHO and analyzed with FACScan™ (Becton Dickinson).
Immunoprecipitation and cross-linking
Mouse EGF (Sigma-Aldrich) and rDIII were labeled with biotin (EZ-Link™
Sulfo-NHS-LC-Biotin; Pierce Chemical Co.). MDA-MB-231 cells (2   10
7)
were washed with binding buffer (DME, 0.2% BSA, and 1 mM glutamine) and
incubated on ice for 2 h with biotinylated ligands. The cross-linker BS
3 (Pierce
Chemical Co.) was added at 1 mM, incubated 2 h on ice, and quenched with
20 mM Tris, pH 7.5, for 15 min at RT. Cells were washed with PBS and ex-
tracted with lysis buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 1% Triton X-100,
1 mM EDTA, 1 mM PMSF, and 1  g/ml each of aprotinin, pepstatin, and leu-
peptin). Lysates were cleared by centrifugation and immunoprecipitated with
anti-EGFR mAb (clone EGFR.1; BD Biosciences) at 4 C. After incubation with
50  l of protein G Sepharose beads (Boehringer), immune complexes were
washed, centrifuged, and proteins were separated by SDS-PAGE (4–12% gra-
dient) under reducing conditions and analyzed by WB.
Precipitation with magnetic beads was done as described in the paragraph
above with the following modifications: MDA-MB-231 lysates were incu-
bated with Dynabeads
® M-280, streptavidin-coated beads (Dynal). The beads
were collected using a magnetic device and washed. Proteins were eluted by
heating the beads with SDS-sample buffer (5 min at 95 C), and the superna-
tant was analyzed by SDS-PAGE and WB. Detection was performed with an
anti-EGFR pAb (sc-03; Santa Cruz Biotechnology, Inc.) and HRP anti–rabbit
secondary antibody at 1:300 and 1:10,000 dilutions, respectively.T
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EGFR phosphorylation
Serum-starved MDA-MB-231 cells were detached with 10 mM EDTA/PBS,
washed, and resuspended in binding buffer. 10
7 cells were kept in suspen-
sion at 37 C for 30 min, then EGF or rDIII was added and cells were incu-
bated at 37 C for 2 or 5 min. Ligands were omitted from negative controls.
Cross-linking was performed as described in Immunoprecipitation and
cross-linking. Cells were lysed for 1 h on ice in lysis buffer with 100 mM
NaF and 1 mM Na3VO4. Lysates were immunoprecipitated with anti-EGFR
mAb, and detection was performed with anti-phosphotyrosine mAb (PY-20;
Transduction Laboratories) at a 1:2,000 dilution, followed by HRP goat anti–
mouse IgG and ECL (PerkinElmer). To confirm equal loading in each lane,
blots were stripped (65 mM Tris, pH 6.7, 2% SDS, and 100 mM  -mercapto-
ethanol at 55 C for 45 min) and reprobed with anti-EGFR pAb (sc-03; Santa
Cruz Biotechnology, Inc.) or mAb (Ab-12, Cocktail R19/48; Neomarker). In
some cases, BS
3 was omitted. With Ln-5, cells were treated for up to 90 min.
I
125-EGF displacement
MDA-MB-231 cells were trypsinized, washed 3  with a buffer containing
DME, 25 mM Hepes, 0.2% BSA, 0.3 mM 1,10 phenanthroline, and 0.16 mM
PMSF, and were then diluted to 2   10
6 ml. 500  l cells were transferred into
coated reaction tubes. Unlabeled competitor molecule (EGF or rDIII) and I
125-
mouse EGF (100  Ci/ g; Amersham Biosciences) were added and cells were
incubated on ice for 3 h. Triplicate 150  l aliquots of the cell label mixture
were layered onto 300  l of a 1:1 mixture of AR-20 and Addid-200 silicon
oils (1,013 kg/cm
3 density; Wacker Chemie). Unbound radioactivity was re-
moved by centrifugation for 1 min at 500 g, followed by removal of the tube
tip at the height of the oil layer. The cell pellet was subjected to  -counting,
and values are presented in cpm. The data were processed using PRISM soft-
ware (GraphPad Software, Inc.). The IC50 was calculated using the linear re-
gression model and either one-site or two-site competition equations to ob-
tain best fit values. To evaluate each fit, e.g., best fit values, 95% confidence
interval and standard error values were considered, and both equations were
compared using the “Fit to two equations and compare with an F-test” op-
tion. The F-test was used to determine a P-value.
ERK1/2 phosphorylation
Cells were grown to 60% confluency and serum-starved for 15 h. Fresh se-
rum-free medium containing 0.5–2  M AG1478 (Calbiochem) or 5–10  g/
ml antibody 528 was added. DMSO was added to the control. After 30
min at 37 C, rDIII, rDIII-V, Ln-5, or EGF was added and cells were incu-
bated at 37 C. Cells were washed in PBS and lysed for 1 h on ice in 0.5 ml
lysis buffer containing one tablet of complete protease inhibitor cocktail
(Roche) per 50 ml. Lysates were cleared by centrifugation for 10 min. Each
sample was divided in half and analyzed for total ERK1/2 content (rabbit
anti-ERK1/2 IgG; Santa Cruz Biotechnology, Inc.) or for phosphorylation
(mAb to phosphorylated ERK1/2; New England Biolabs, Inc.) by WB.
Cell migration
Migration was performed in Transwell chambers (8- m pores; Corning
Costar) coated on the underside with 0.25  g/ml rat Ln-5 for MDA-MB-
231 cells, and with 1  g/ml for MCF-7 and MCF10A cells at 4 C overnight.
Rat Ln-5 was purified from spent 804G cell media (Hormia et al., 1995).
Filters were washed, blocked with 5% skim milk, PBS containing 0.2%
Tween 20, and 0.02% azide for 2 h at RT, and washed again. Membranes
were placed into the lower chamber containing 600  l serum-free DME.
Trypsinized cells were washed and plated at 0.6–1   10
5 cells/well. rDIII,
EGF, or antibody LA1 (5–10  g/ml) were added to the lower and/or upper
chambers at various concentrations to obtain maximum stimulation (see
legend to Fig. 8). Chambers were incubated 6 or 18 h at 37 C. Nonmigra-
tory cells were removed from the upper membrane with a cotton swab. Fil-
ters were fixed, stained with HEMA 3
® Stain Set (Biochemical Sciences),
and cells were counted in eight random fields on each of two filters for
each condition. The significance of each migration assay was evaluated
using the t test assuming unequal variances. P-values lower than 0.05 were
considered statistically significant. To determine statistical significance be-
tween more than two groups, ANOVA was used.
cDNA microarray
MCF-7 cells at 60% confluency were serum-starved for 8 h and incubated
for 24 h serum-free. 1  g total RNA was isolated with RNeasy mini kit
(QIAGEN) and amplified by in vitro transcription (Luo et al., 1999). 5  g
amplified RNA was labeled with Cy3 or Cy5-dCTP (Amersham Bio-
sciences). Fluorescent cDNAs were hybridized to a custom cDNA mi-
croarray chip. Fluorescent images were captured using a laser scanner
(ScanArray™ 5000; GSI Lumonics).
Semi-quantitative RT-PCR
The One-step RT-PCR™ kit (QIAGEN) was used with 2  g total MCF-7
RNA, and the MMP-2 primers 5 -TCAGATCCGTGGTGAGATCTT-3  and
5 -GCTCTTCAGACTTTGGTTCTC-3 . As a control, GAPDH was amplified
using the primers 5 -TGAAGGTCGGAGTCAACGGAT-3  and 5 -GTCAT-
GAGTCCTTCCACGATA-3 . For each cDNA, the optimal cycle number
was determined to ensure that DNA amplification was in the linear range.
Cleavage of Ln-5 by MMP-2
0.5–1.0  g of rat Ln-5 (Hormia et al., 1995) was incubated with 0.1  M of
p-aminophenyl-mercuric acetate (APMA)–activated MMP-2 for 17 h at
37 C in 50 mM Tris, pH 7.5, 0.005% Brij-35, and 5 mM CaCl2 in a volume
of 30  l. Each reaction mixture was analyzed by SDS-PAGE and WB.
Collection of mammary tissue
Induction of synchronized involution and collection of mammary tissue
was performed as described previously (Fata et al., 2001). The second and
third thoracic mammary glands were homogenized in lysis buffer (10 mM
Tris, pH 7.6, 5 mM EDTA, 50 mM NaCl, 1% Triton X-100, 30 mM
Na4P2O7, 200  M Na3VO4, 1 mM PMSF, 5  g/ml aprotinin, 1  g/ml pep-
statin, and 2  g/ml leupeptin) for WB. The homogenates were centrifuged
for 20 min at 4 C. Protein concentration was determined using Dc Bio-Rad
assay reagent. Supernatants and insoluble pellets were stored at  70 C un-
til analyzed by SDS-PAGE and WB.
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